Composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases

A technology for respiratory diseases and virus infection, which is applied in the field of compositions for respiratory diseases and other diseases, and can solve the problems of no seasonality, rising epidemics, etc.

Inactive Publication Date: 2020-09-25
WUXI HONGRUI BIOMEDICAL TECH CO LTD
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] 3. No seasonality: Generally speaking, influenza viruses and other viruses are not suitable for survival in high-temperature and humid environments, and low-temperature and dry climates are suitable for mass reproduction. Therefore, influenza mostly occurs in spring, and the epidemic situation in summer decreases, and autumn and winter alternate. then the epidemic rises
There is no report on the research in this area

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases
  • Composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Mix 35g of L-ascorbyl palmitate, 2g of silicon dioxide, 60g of powdered soybean lecithin and 3g of light calcium carbonate powder to form 100g of matrix.

[0048] 331 g of alliin with a purity of 98%, 200 g of alliinase, and 399 g of camostat mesylate were added to the 70 g of the matrix, and stirred while adding to make them evenly mixed with the matrix. That is, 1000 g of this composition was obtained.

Embodiment 2

[0050] 1 mg of the composition prepared in Example 1 was added to 100 ml of DMEM (Dulbecco'smodified Eagle's medium) medium that added 5% fetal bovine serum to obtain 10 μM allicin and 10 μM camostat mesylate simultaneously. Contains inhibitor DMEM.

[0051] Human bronchial epithelial Calu-3 cells in a 96-well plate were treated with inhibitor-containing DMEM at 37°C for 30 min. In DMEM containing inhibitors, use about 10 6 SARS-CoV infection in PFU10 5 cells (MOI, 10), and then cultured at 37°C for 5hrs. In the blank control group, fresh DMEM was used instead of inhibitor-containing DMEM. Cellular RNA was isolated by adding 200 μl of Isogen reagent. Real-time PCR was used to estimate the amount of newly synthesized mRNA9 from SARS-CoV. Viral mRNA levels were normalized to the expression level of the cellular housekeeping gene encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

[0052] The results showed that the combination of 10 μM allicin and 10 μM camostat me...

Embodiment 3

[0054] 1 mg of the composition prepared in Example 1 was added to 100 ml of DMEM (Dulbecco'smodified Eagle's medium) medium that added 5% fetal bovine serum to obtain 10 μM allicin and 10 μM camostat mesylate simultaneously. Contains inhibitor DMEM.

[0055] Human bronchial epithelial Calu-3 cells (10 6 cells) were seeded into 24-well plates, and 10 cells were added to DMEM 4 PFU of SARS-CoV (MOI, 0.01) and incubated at 37°C for 2 hours. Cells were washed twice with PBS to remove residual virus, and DMEM was replaced with freshly prepared inhibitor-containing DMEM. In the blank control group, fresh DMEM was used instead of inhibitor-containing DMEM. Cellular RNA was isolated from cells in four wells every 24 hours for 6 days by adding 400 μl of Isogen reagent. How quickly SARS-CoV grows was estimated by measuring viral mRNA9 using real-time PCR.

[0056] The results showed that in cells cultured in the presence of 10 μM allicin and 10 μM camostat mesylate at the same time...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of formulas of medicament for preventing and treating physical diseases and particularly relates to composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases. Alliin, alliinase and type II transmembrane serine protease inhibitor are taken as basic effective ingredients, the compositionis administered in a way of inhalation by the lung, can kill physical diseases caused by bacteria such as methicillin-resistant staphylococcus aureus, multidrug resistance type escherichia coli, multidrug resistance type pseudomonas aeruginosa, multidrug resistance type mycobacterium tuberculosis and the like, viruses such as SARS-CoV-2 and the like, fungi such as multidrug resistance type candida albicans and the like, parasites and the like in a respiratory system and also can prevent fat accumulation in blood vessels of a human body, reduce the blood pressure, the cholesterol level in blood and destroy cancer cells of multiple epithelial tumors of breast cancer, ovarian cancer, colon cancer, renal carcinoma, liver cancer, lung cancer, mesothelioma and prostatic cancer, and the composition has no any toxic or harmful functions and risks and has broad application prospects.

Description

technical field [0001] The invention belongs to the technical field of formulations of medicaments for preventing and treating physical diseases, in particular to a composition capable of preventing and treating respiratory diseases such as novel coronavirus infection and other diseases. Background technique [0002] Respiratory system diseases, especially respiratory infectious diseases caused by the outbreak of airborne infectious agents such as bacteria and viruses, are one of the major challenges facing human survival. The current global pandemic of novel coronavirus pneumonia (COVID-19) is a new challenge brought to us by the novel coronavirus (SARS-CoV-2). The virus: [0003] 1. High rate of human-to-human transmission: The SARS virus in 2002 and the MERS virus in 2012 were contained because they only had a high rate of transmission between animals and humans, while the rate of human-to-human transmission was very low Low, so it can be effectively controlled as long ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/51A61K45/06A61K9/14A61P31/14A61P31/04A61P31/16A61P31/20A61P31/18A61P31/22A61P31/10A61P33/02A61P35/00A61P9/12A61P3/06A61P7/02A61P9/10A61K31/198
CPCA61K38/51C12Y404/01004A61K31/198A61K45/06A61P31/14A61P31/04A61P31/16A61P31/20A61P31/18A61P31/22A61P31/10A61P33/02A61P35/00A61P9/12A61P3/06A61P7/02A61P9/10A61K9/0075A61K9/141Y02A50/30
Inventor 汤宁齐绪林汤鲁宏
Owner WUXI HONGRUI BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap